In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of ...
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Insmed (INSM – Research Report), with a price target of $98.00.
In a note early Tuesday, TD Cowen analyst Ritu Baral said that the outcome of the brensocatib trial at both dosage levels was ...
Distributor relationships are being explored in the Middle East and North Africa. Ritu Baral, Analyst, TD Cowen: We’re going to go ahead and get started. Thank you very much for joining us for ...